Astellas acquires Audentes to create ‘industry leading’ gene therapy company

Astellas is aiming to create an “industry leading” gene therapy company with the $3 billion acquisition of San Fran biotech, Audentes Therapeutics.

The acquisition sees Astellas add a fifth ‘Primary Focus in Genetic Regulation’ to its ‘Astellas Focus Area’ approach. Under this focus, gene therapy will be a key driver of the company’s future growth, it said.

“Audentes has developed a robust pipeline of promising product candidates which are complementary to our existing pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM),” said Kenji Yasukawa, President and CEO of Astellas.

“By joining together with Audentes’ talented team, we are establishing a leading position in the field of gene therapy with the goal of addressing the unmet needs of patients living with serious, rare diseases.”

The deal is expected to be completed in Q1 2020.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news